Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Retained Earnings (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Retained Earnings for 13 consecutive years, with -$76.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings fell 11.47% year-over-year to -$76.9 million, compared with a TTM value of -$76.9 million through Dec 2025, down 11.47%, and an annual FY2025 reading of -$76.9 million, down 11.47% over the prior year.
  • Retained Earnings was -$76.9 million for Q4 2025 at Abvc Biopharma, down from -$74.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $981718.0 in Q3 2021 and bottomed at -$76.9 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$42.6 million, with a median of -$52.5 million recorded in 2022.
  • The sharpest move saw Retained Earnings soared 104.72% in 2021, then tumbled 16162.05% in 2025.
  • Year by year, Retained Earnings stood at -$38.5 million in 2021, then plummeted by 42.68% to -$54.9 million in 2022, then surged by 100.94% to $516387.0 in 2023, then crashed by 13452.35% to -$68.9 million in 2024, then dropped by 11.47% to -$76.9 million in 2025.
  • Business Quant data shows Retained Earnings for ABVC at -$76.9 million in Q4 2025, -$74.1 million in Q3 2025, and -$72.0 million in Q2 2025.